Volastra Therapeutics Inc. has entered into partnerships with Microsoft Corp., Function Oncology Inc. and Tailor Bio Ltd. with the goal of expanding the potential use of its KIF18A inhibitors.
Investigators at Incyte Corp. have reported details on the discovery and preclinical characterization of new potent and selective inhibitors of cyclin-dependent kinase 2 (CDK2) as potential anticancer candidates.
Researchers from Merck & Co. Inc. have presented the discovery of inhibitors of the YAP/TAZ-TEAD complex as potential anticancer agents. YAP and its paralogue TAZ act as terminal effectors of the Hippo signaling pathway by regulating the transcriptional activity of the different TEAD isoforms.
Auron Therapeutics Inc. has described proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a histone acetyltransferase KAT2A and/or KAT2B (PCAF)-targeting moiety through a linker.
Nutshell Biotech (Shanghai) Co. Ltd. has synthesized macrocyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Vesper Bio ApS has disclosed sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, hearing loss, inflammation, neurodegeneration, pain, and psychiatric, cardiovascular and renal disorders, among others.
Scientists at the Karolinska Institutet in Sweden have found a new region in the c-Myc oncogene that would allow the development of a binding compound to target it. Their discovery is based on a structural switch that leads to open and closed conformations of the domain, allowing or not its interaction with a protein required for the oncogenic activity of c-Myc.
Researchers from Jinan University (Guangdong) and affiliated organizations reported new data detailing the discovery and preclinical characterization of novel fibroblast growth factor receptor 4 (FGFR4) inhibitors for the treatment of hepatocellular carcinoma (HCC).
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key regulator of physiological antigen receptor signaling in B cells and T cells, as it is the only component of the MALT1-BCL10-CARD11 (CBM) signalosome with proteolytic activity.
Ubiquigent Ltd. has signed an agreement with Debiopharm International SA to support the development of Debiopharm’s preclinical ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitor program, Debio-0432.
RSS
